Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Medical Countermeasures for Botulinum Neurotoxins

by Global Biodefense Staff
August 16, 2015
Botulinum Neurotoxin Structure

Image courtesy of UC Irvine

Three contracts in support of a Defense Threat Reduction Agency (DTRA) botulinum neurotoxin countermeasure research consortium will receive funding extensions through the end of  2015, according to a recent announcement from the U.S. Army.

The supported effort is entitled “Development of Medical Countermeasures for Botulinum Neurotoxin Intoxication Focused on Therapeutics and Neuroregenerative Medicines.” Under the multicenter consortium, the following three organizations were selected for FY2015 research contracts to be conducted in coordination with U.S Army Medical Research Institute of Chemical Defense (USAMRICD) collaborators:

Montclair State University is contributing to the botulinum drug discovery effort by synthesizing small molecule drug candidates for treatment of botulinum toxin exposure and optimizing their pharmaceutical properties.

The Institute of Advanced Sciences will support the efforts at the USAMRICD by performing high throughput screening of natural product and small molecule libraries.

Ossianix Inc. will provide an alternative to traditional inhibitors by developing small single chain shark antibodies as potential inhibitors for catalytic activity.

The extension through December 31, 2015 is to allow additional research for USAMRICD to complete the first cycle of this consortium effort. After discussions between the collaborating parties it was determined that additional time and funding would be needed to obtain the necessary objectives prior to the next research cycle.

Funding in the amount of $75,000 for MSU and $75,000 for the Institute of Advanced Sciences will be provided to complete the first cycle of the research. Ossianix will be receiving a completion date extension using the funding made available at the time of initial contract. Once approved, these three research contracts will end on December 31, 2015.

Research contracts to be performed in Fiscal Year 2016 to support the development of medical countermeasures will be addressed competitively through the U.S Army Medical Research and Materiel Command’s (USAMRMC’s) Broad Agency Announcement 15-1.

Tags: AwardsBotulinum Neurotoxin

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC